The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...

Nov 27, 2025 · Explore the current issue of The New England Journal of Medicine (Vol. 393 No. 21).

Explore the index of articles published by the New England Journal of Medicine, from original research to videos in clinical medicine and more.

In patients with hereditary hemorrhagic telangiectasia, treatment with engasertib reduced nosebleed frequency and duration over 12 weeks, with mild reversible rash as the most …

Nov 29, 2025 · Explore this issue of The New England Journal of Medicine (Vol. 0 No. 0).

Index of all Issues from New England Journal of Medicine

Tumor lysis syndrome has evolved and become less predictable with the introduction of new cancer therapies. This review explores risk factors and causes of the syndrome, as well as …

Jun 20, 2025 · Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We conducted a phase …

The New England Journal of Medicine (NEJM) is recognized as the world’s leading medical journal and website. Published continuously for over 200 years, NEJM delivers high-quality, …

Sep 9, 2024 · Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals. In these phase 3A, …